Sentences with phrase «key drug targets»

Postdoctoral fellow Aaron Gitler now is searching for the original defect that the Parkinson's protein triggers in yeast cells in hopes of identifying the underlying disease pathway and key drug targets.

Mayo Clinic researchers have identified that a key drug target, CDK4 / 6, regulates a cancer metastasis protein, SNAIL, and drugs that inhibit CDK 4/6 could prevent the spread of triple - negative breast cancer.

Not exact matches

The experimental drug targets hormones that are key in regulating the body's blood - sugar levels: GLP - 1, GIP, and glucagon.

(Reuters)- Celgene Corp on Thursday reported third - quarter sales of its key psoriasis drug Otezla that badly missed expectations and significantly scaled down its 2020 targets for product sales and earnings, sending its shares tumbling 18 percent.

Additional clinical trial data later this year on Tesaro's key drug, Niraparib, which targets advanced solid tumors in ovarian and breast cancers, could help narrow the valuation gap, the people said.

Key findings presented at AACR included sustained peripheral NK and T cell expansion, doses were well - tolerated and the drug candidate's role as a long - acting CD122 agonist without targeting CD25.

The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment.

(Reuters)- Alnylam Pharmaceuticals Inc's RNAi - based drug that targets a rare genetic disease met the main goal of a key study, in a breakthrough for the new class of medicines that works by blocking disease - causing proteins.

Fiers discovered a key protein on the influenza virus that could serve as a target for a universal vaccine; the drug has shown promise in an early clinical trial.

«Molecular scissors» could be key to cutting off diseases including HIV infection: Newly discovered pathway could be drug target, researchers say.»

About 15 to 20 % of breast cancers are classified as «triple negative,» so called because these tumors do not express three key proteins that are biomarkers and / or drug targets for breast cancer: the estrogen receptor, the progesterone receptor, and HER2 (a member of the epidermal growth factor receptor family).

The drug may or may not become a breakthrough Alzheimer's treatment — it's too soon to say — but either way it will probably answer a key question: Have researchers been aiming at the right target?

Treatment for advanced melanoma has seen success with targeted therapies — drugs that interfere with division and growth of cancer cells by targeting key molecules — especially when multiple drugs are used in combination.

Óscar Llorca and his team have used this technique to learn about the structure and functioning of a complex system called R2TP, which is involved in various key processes for cell survival such as the activation of the kinases mTOR, ATR and ATM, proteins that are the target of various cancer drugs currently being developed.

The researchers blocked BH4 production using a specifically designed drug that targets sepiapterin reductase (SPR), a key enzyme that makes BH4.

«With a key challenge being that resistance to drugs is spreading faster than new drugs are being developed and approved,» they suggest that «the use of encapsulated, nanobody - targeted drugs as described here has the potential to reverse resistance to many first - line treatments.»

This relationship will be a key to developing any drugs to target this mechanism.»

Using newly discovered information, the researchers made significant advances in developing a family of drug candidates that target a receptor known as peroxisome proliferator - activated receptors gamma (PPARγ), a key regulator of stem cells controlling bone formation and bone resorption and a master regulator of fat.

So, if a pharmaceutical company creates an Alzheimer's drug to target memory based on research into one type of memory — the part of the brain responsible for finding missing objects, for example — but doesn't also have data on the type of memory that helps individuals remember the important people, places and things in their life, it runs the risk of producing a product that helps a person remember where they put the car keys, but not how they met their spouse.

Professor Geoff Pilkington, study co-author and Head of the Brain Tumour Research Centre, said: «Although this work is still at an early stage, we have demonstrated key elements that are associated with tumour cell binding to blood vessels and this may provide a target for future drug development to prevent the development of secondary tumours in the brain.

Her group is actively working to identify new molecules key to the disease process that could become potential drug targets.

«The goal of our research is to identify key molecules that govern metastasis and use them as targets for the development of new drugs.»

Many of these new drugs promise to be more effective because they target key pathways of cancer cells more specifically.

Not surprisingly, many researchers and patient groups watching the new initiative say funding for basic research that identifies new drug targets is a key issue.

The microtubule tracks are vital for functions such as cell division and are a key target for key cancer drugs.

To narrow down the number of chemical compounds that could be potential drug candidates, scientists utilize computer models that can predict how a particular chemical compound might interact with a biological target of interest — for example, a key protein that might be involved with a disease process.

«This supports other data that GABA receptors are key in the actions of alcohol and that targeting this interaction is a viable approach to reducing alcohol intake,» says David Nutt of Imperial College London, former head of the British government's advisory committee on drugs.

Research led by scientists at the University of Birmingham shows more precisely how G protein - coupled receptors, which are the key target of a large number of drugs, work.

Dr. Qimin Zhan, Principal Investigator of this project and the Director of State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences Cancer Hospital, said, «For sure, the findings of this project provide novel insights into understanding of underlying mechanism for this malignant ESCC, and enable us to explore potential diagnostic biomarkers and drug targets, and to develop useful clinical therapeutic approaches.

For Alzheimer's disease, the aim is for the investigational drug to target major pathologies of the disease and selectively activate a key receptor in the brain.

Researchers at the University of Chicago Medical Center have isolated the gene for a component of the elusive molecular machinery that plays a key role in making cancer cells immortal, offering scientists a tantalizing target for new anticancer drugs of greater effectiveness and lower toxicity.

In this review, we highlight this technological opportunity by focusing on key target organs associated with drug safety and metabolism.

Abstract Pentameric channel - receptors, including nicotinic acetylcholine, glycine and GABAA receptors, play a key role in fast excitatory and inhibitory transmission in the nervous system and are the target of numerous therapeutic and addictive drugs.

The structures of membrane - bound BCL - 2 proteins have been long sought - after because they hold the keys for understanding the mechanistic basis of activity and for the development of selective drugs free of off - target effects.

Dopamine release in the nucleus accumbens is considered to be a key target for psychostimulant drugs.

The drug, marketed as Lucentis, targets a molecule called vascular endothelial growth factor (VEGF), a key player in the growth of blood vessels.

deCODE is a global leader in gene discovery — our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease.

It is rarely found in healthy tissue so the drug only targets cancerous cells — this is key in reducing side effects.

«Seeing the design of this key protein provides a target for a potential vaccine or even a therapeutic drug,» Smith said.

Researchers at Whitehead Institute have identified a key target protein of glucocorticoids, the drugs that are used to increase red blood cell production in patients with certain types of anemia, including those resulting from trauma, sepsis, malaria, kidney dialysis, and chemotherapy.

To understand the selection mechanism behind mutations, network - based studies were used to estimate the importance of a mutated protein compared to non-mutated ones in signalling and protein — protein interaction networks.10, 11,12,13 Proteins mutated in cancer were found having a high number of interacting partners (i.e., a high degree of connectivity), which indicates high local importance.10 Mutated proteins are also often found in the centre of the network, in key global positions, as quantified by the number of shortest paths passing through them if all proteins are connected with each other (i.e., they have high betweenness centrality; hereafter called betweenness).11, 12 Mutated proteins also have high clustering coefficients, which means their neighbours are also neighbours of each other.10, 13 Moreover, neighbourhood analysis of mutated proteins have been previously successfully used to predict novel cancer - related genes.14, 15 However, to the best of our knowledge, no study has concentrated particularly on the topological importance of first neighbours of mutated proteins in cancer, and their usefulness as drug targets themselves.

It's a compelling idea (enough to sway a key ally played by Daniel Kaluuya), and a reminder that throughout the African diaspora, the black - white power balance remains as it is courtesy of Jim Crow practices designed to keep minorities in check: persistent segregation, broken drug laws, racially targeted policing, disproportionately high incarceration rates — all of which are identified and indicted by Coogler's truth - to - power script.

Tags for this Online Resume: Biotechnology, Diagnostic, Pharmaceutical, Marketing, Oncology, Strategy, Brand Planning, Global Marketing, New Product Planning, Pricing, Market Research, Brand Leader, Commercial, Commercialization, Launch, Drug Development, Matrix, Cross Functional, Digital, KOL, Key Opinion Leader, Portfolio, Management, Brand Team, Agency, Diabetes, Cardiovascular, Commercial Strategy, Corporate Affairs, Communications, Hematology, Urology, Neuroscience, phase 2, phase 3, phase II, phase III, Powerpoint, Excel, Word, Part B, Part D, Seattle, Portland, San Francisco, Executive Director, Senior Director, Director, Vice President, Go - To - Market, Value Proposition, Go To Market, Launch Planning, Access, Reimbursement, Payer, Market Development, Market Assessment, Pipeline, In - Line, Brand Management, Coaching, Leadership, Marketing Strategies, Marketing Strategy, Strategic Planning, Autoimmune, Early Stage, Pre-Launch, Pre Launch, Regulatory, Operations, Marketing Plan, Business Plan, Business Development, Market Analysis, Segmentation, Targeting, Companion Diagnostic, Target Product Profile, Pre-Clinical, Competition, Positoning, Branding, Sales, Budget, Sales Management, Communication Plan, Publication Plan, Project Management, Genetic, Genomic, Lifecycle, Long Range, Device, Late Stage, Direct Report, Indirect Report, New Molecular Entities, Competitive, Biopharmaceutical, Medical Device, Non-Promotional, Tactical, Execution, IND, Revenue, Partner, Clinical, Consult, Analytical, Problem Solver, Global, International, Affordable Care Act, Lymphoma, Leukemia, Prostate, Breast, Cancer, OPDP, Promotional, Promotions, Brand, Healthcare, Distribution, Infrastructure, IMS, Priority Review, Experienced, Patient, Consumer

Key actions of Reducing Harm, Supporting Recovery include: • Introduction of a pilot supervised injecting facility in Dublin's city centre; • Establishment of a Working Group to examine alternative approaches to the possession for personal use of small quantities of illegal drugs; • Funding for a programme to promote community awareness of alcohol - related harm; • A new targeted youth services scheme for young people at risk of substance misuse in socially and economically disadvantaged communities; • Expansion of drug and alcohol addiction services, including residential services; • Recruitment of 4 Clinical Nurse Specialists and 2 Young Persons Counsellors to complement HSE multi-disciplinary teams for under 18s; • Recruitment of 7 additional drug - liaison midwives to support pregnant women with alcohol dependency; • Establishment of a Working Group to explore ways of improving progression options for people exiting treatment, prison or community employment schemes, with a view to developing a new programme of supported care and employment.